Press release
Ischemic Stroke Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharma, Genentech, Inc., NoNO, Pharming Technologies B.V., Biogen, Athersys, Inc.
"Ischemic Stroke Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ischemic Stroke Market.
The Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Ischemic Stroke Pipeline Report: https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Ischemic Stroke treatment therapies with a considerable amount of success over the years.
• Ischemic Stroke companies working in the treatment market are TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others, are developing therapies for the Ischemic Stroke treatment
• Emerging Ischemic Stroke therapies in the different phases of clinical trials are- Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others are expected to have a significant impact on the Ischemic Stroke market in the coming years.
• In January 2024, Aruna Bio has revealed intentions to commence a Phase I/II clinical trial of AB126 for treating acute ischemic stroke by the first half of 2024. This decision follows the clearance of the company's investigational new drug (IND) application by the US Food and Drug Administration (FDA) for its lead program, AB126. This milestone represents the first IND approval for Aruna Bio's platform.
Ischemic Stroke Overview
An ischemic stroke, also known as a brain attack, happens when a blood artery in the brain breaks or when something stops the blood supply to a portion of the brain. Either way, certain brain regions suffer harm or even die. A stroke can result in death, long-term incapacity, or permanent brain damage.
Get a Free Sample PDF Report to know more about Ischemic Stroke Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:
• Microlyse: TargED Biopharmaceuticals
• ST-01: Saillant Therapeutics
• Elezanumab: AbbVie
• RNS60: Revalesio Corporation
• BIIB131: Biogen
• Glenzocimab: Acticor Biotech
• 3K3A-APC: ZZ Biotech
• Nelonemdaz: GNT Pharma
• MultiStem: Athersys, Inc.
• Glenzocimab: Acticor Biotech
• Elezanumab: AbbVie
• LT3001: Lumosa Therapeutics
• AVLX-144: Avilex Pharma
Ischemic Stroke Route of Administration
Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Ischemic Stroke Molecule Type
Ischemic Stroke Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Ischemic Stroke Pipeline Therapeutics Assessment
• Ischemic Stroke Assessment by Product Type
• Ischemic Stroke By Stage and Product Type
• Ischemic Stroke Assessment by Route of Administration
• Ischemic Stroke By Stage and Route of Administration
• Ischemic Stroke Assessment by Molecule Type
• Ischemic Stroke by Stage and Molecule Type
DelveInsight's Ischemic Stroke Report covers around 55+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Ischemic Stroke product details are provided in the report. Download the Ischemic Stroke pipeline report to learn more about the emerging Ischemic Stroke therapies
https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Ischemic Stroke Therapeutics Market include:
Key companies developing therapies for Ischemic Stroke are - Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Athersys, Inc., Tarveda Therapeutics, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Avilex Pharma, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others.
Ischemic Stroke Pipeline Analysis:
The Ischemic Stroke pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Ischemic Stroke with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.
• Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ischemic Stroke market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Ischemic Stroke drugs and therapies
https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Ischemic Stroke Pipeline Market Drivers
• Rising incidence of Acute Ischemic Stroke, increasing prevalence of lifestyle associated disorders such as diabetes and hypertension, rising geriatric population are some of the important factors that are fueling the Ischemic Stroke Market.
Ischemic Stroke Pipeline Market Barriers
• However, challenges associated with the clinical research, challenges with the diagnosis of AIS and other factors are creating obstacles in the Ischemic Stroke Market growth.
Scope of Ischemic Stroke Pipeline Drug Insight
• Coverage: Global
• Key Ischemic Stroke Companies: TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others
• Key Ischemic Stroke Therapies: Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others
• Ischemic Stroke Therapeutic Assessment: Ischemic Stroke current marketed and Ischemic Stroke emerging therapies
• Ischemic Stroke Market Dynamics: Ischemic Stroke market drivers and Ischemic Stroke market barriers
Request for Sample PDF Report for Ischemic Stroke Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Ischemic Stroke Report Introduction
2. Ischemic Stroke Executive Summary
3. Ischemic Stroke Overview
4. Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment
5. Ischemic Stroke Pipeline Therapeutics
6. Ischemic Stroke Late Stage Products (Phase II/III)
7. Ischemic Stroke Mid Stage Products (Phase II)
8. Ischemic Stroke Early Stage Products (Phase I)
9. Ischemic Stroke Preclinical Stage Products
10. Ischemic Stroke Therapeutics Assessment
11. Ischemic Stroke Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ischemic Stroke Key Companies
14. Ischemic Stroke Key Products
15. Ischemic Stroke Unmet Needs
16 . Ischemic Stroke Market Drivers and Barriers
17. Ischemic Stroke Future Perspectives and Conclusion
18. Ischemic Stroke Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Ischemic Stroke Market https://www.delveinsight.com/report-store/ischemic-stroke-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ischemic Stroke Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Ischemic Stroke Epidemiology https://www.delveinsight.com/report-store/ischemic-stroke-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ischemic Stroke Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Alcohol Use Disorder Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market
DelveInsight's "Alcohol Use Disorder (AUD) Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AUD, historical and forecasted epidemiology, as well as the AUD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Congestive Heart Failure Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical and forecasted epidemiology as well as the CHF market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
CDMO Market
https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market
Global CDMO market was valued at USD 100.02 billion in 2021, growing at a CAGR of 6.25% during the forecast period from 2024 to 2030, in order to reach USD 143.87 billion by 2030. Factors such as rising prevalence of various chronic and acute diseases leading to growing requirement of drugs, rising popularity of biologics as a treatment option are further expected to drive the demand for services offered by CDMOs as biologics being more complex than small molecules require elaborate facilities for product development.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ischemic Stroke Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharma, Genentech, Inc., NoNO, Pharming Technologies B.V., Biogen, Athersys, Inc. here
News-ID: 3654266 • Views: …
More Releases from DelveIinsight Business Research
Thymidine Kinase 2 Deficiency Market Insights: Unmet Needs and Emerging Therapie …
The Thymidine Kinase 2 deficiency (TK2d) market is poised for substantial growth in the coming decade, fueled by increasing awareness of this rare genetic disorder and the development of promising therapies like MT1621 (UCB).
DelveInsight's "Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast - 2034" report delivers comprehensive insights into the current TK2d landscape and future market trends across the 7MM (United States, EU4, the United Kingdom, and Japan).…
Pigment Epithelial Detachment Market Outlook: Aging Population, AI-Driven Diagno …
Recent analysis by DelveInsight indicates that the retinal pigment epithelium market is poised for notable growth, with the 7MM expected to achieve a respectable CAGR. This growth is being fueled by several factors, including an aging population, advancements in AI-driven diagnosis, industry collaborations, and novel therapeutic options. Key retinal pigment epithelium companies include Sumitomo Pharma, Healios K.K., Eyestem Research, Luxa Biotechnology, Regenerative Patch Technologies, Lineage Cell Therapeutics, Katairo GmbH, Visgenx…
Chronic Obstructive Pulmonary Disease Market Forecast 2024-2034: Competitive Int …
The chronic obstructive pulmonary disease (COPD) market is projected to experience steady growth in the coming years, driven primarily by increasing diagnosed prevalent cases and the introduction of novel biologics and combination therapies by key COPD companies, including Sanofi, Regeneron Pharmaceuticals, GlaxoSmithKline, AstraZeneca, and Amgen, among others. This market expansion reflects advancements in targeted therapeutic approaches, particularly for patients with specific phenotypes, improved diagnostic capabilities, and rising awareness among healthcare…
Blastic Plasmacytoid Dendritic Cell Neoplasm Treatment Landscape Transforms with …
The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market across the 7MM is poised for significant growth through 2034. This growth is driven by advancements in targeted therapies, increased awareness of the disease among healthcare professionals, and ongoing research and development efforts. Major pharmaceutical and biotech companies, including AbbVie, ImmunoGen, Mustang Bio, Genentech, Stemline Therapeutics, Jazz Pharmaceuticals, Menarini Group, Cellex Patient Treatment GmbH, and Xencor, are actively engaged in the BPDCN…
More Releases for Ischemic
Acute Ischemic Stroke (AIS) Market Demand 2034
Market Overview
The Acute Ischemic Stroke (AIS) Market continues to expand due to rising global incidence of stroke, increasing aging populations, and rapid adoption of advanced diagnostic and therapeutic technologies. AIS occurs when a blood clot obstructs an artery supplying the brain, leading to reduced blood flow and neuronal damage. The disease represents the majority of all stroke cases worldwide, and healthcare systems are increasingly prioritizing early diagnosis and treatment to…
Rising Hypertension Fuels Growth In Acute Ischemic Stroke Therapeutics Market: K …
The Acute Ischemic Stroke Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Acute Ischemic Stroke Therapeutics Market Size During the Forecast Period?
The acute ischemic stroke therapeutics market has experienced significant growth in recent years. It is projected to rise from…
Ischemic Stroke Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Ischemic Stroke Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Ischemic Stroke Pipeline Report
• Over 50+ Ischemic Stroke…
Ischemic Cardiomyopathy Treatment Market Growth, Challenges, Opportunities and E …
"The new report has been added by qyresearch.com to provide detailed insight into the global Ischemic Cardiomyopathy Treatment market. The study will help to get a better understanding about the Ischemic Cardiomyopathy Treatment industry competitors, a channel for the distribution, Ischemic Cardiomyopathy Treatment growth potential, potentially disruptive trends, Ischemic Cardiomyopathy Treatment industry product innovations, market size value/volume (regional/country level, Ischemic Cardiomyopathy Treatment industry segments), market share of top players/products.
Due to…
Transient Ischemic Attack Market Forecast by 2025
Recent Transient Ischemic Attack market research and the current scenario as well as future market potential of "Global Transient Ischemic Attack Market Professional Survey Report 2020". The Transient Ischemic Attack Market comprehensively describes the market and prognosticates it to describe a highly illustrious growth during the anticipated years. The report offers an in-depth analysis of current and future Transient Ischemic Attack Market outlook across the globe. The report is projected…
Acute Ischemic Stroke Diagnosis And Treatment Market : Increased Usage of Advanc …
A recent report on global acute ischemic stroke diagnosis and treatment market has been analyzed by Transparency Market Research (TMR). The market for acute ischemic stroke diagnosis and treatment is expected to increase during the forecast period with the increasing incidence of strokes, technically advanced techniques, and successful results through treatment surgeries. Technological advancement and constant efforts made by leading companies are providing improved treatments for people suffering from ischemic…
